COMPASS Pathways Plc American Depository Shares (CMPS)
Stock · NASDAQ · Health Care
$10.74as of 10/16/2026
Price chart
Active signals
CMPS Signal Track Record
How signals performed across all stocks →What CMPS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | -1.0% | 47% | September 9, 2026 |
| Bollinger Band Breakdown | 21 | +0.8% | 52% | October 1, 2026 |
| Bollinger Band Breakout | 22 | +1.8% | 55% | September 9, 2026 |
| 200-Day Moving Average TouchActive now | 14 | -3.4% | 36% | April 14, 2026 |
| Any 20-session window (baseline) | -0.1% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CMPS
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx L…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 156
- Website
- compasspathways.com/
Fundamentals
- 1-day range
- $10.72$11.59
- Market cap
- $1.83B
- P/E (trailing)
- —
- P/E (forward)
- -7.50
- EPS (trailing)
- $-3.47
- Dividend yield
- —
- Beta
- 2.42
- Avg. volume
- 2.78M
Forecasts
16 analyst ratings
COMPASS Pathways Plc American Depository Shares Competitors
Chosen by industry and closest market cap.
- CMPSCOMPASS Pathways Plc American Depository Shares$10.75▼ 7.49%Market cap $1.83BP/E —$4.88$15.87
- NBTXNanobiotix S.A. American Depositary Shares$21.3▼ 4.18%Market cap $1.83BP/E —$13.1$47.66
- DMRADamora Therapeutics Inc. Ordinary Shares$18.44▼ 1.60%Market cap $1.84BP/E —$16.5$34.89
- BCAXBicara Therapeutics Inc. Common Stock$16.78▼ 4.77%Market cap $1.81BP/E —$13.7$30.99
- ANIPANI Pharmaceuticals Inc.$72.29▲ 0.01%Market cap $1.86BP/E 15.16$69.58$97
- NAMSWNewAmsterdam Pharma Company N.V. Warrant$9▼ 17.81%Market cap $1.87BP/E —$9.79$30.45
- KARDKardigan Inc. Common Stock$13.03▼ 6.12%Market cap $1.79BP/E —$12.23$27
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CMPS COMPASS Pathways Plc American Depository Shares | $1.83B | — | $10.75 | ▼ 7.49% | $4.88$15.87 |
| NBTX Nanobiotix S.A. American Depositary Shares | $1.83B | — | $21.3 | ▼ 4.18% | $13.1$47.66 |
| DMRA Damora Therapeutics Inc. Ordinary Shares | $1.84B | — | $18.44 | ▼ 1.60% | $16.5$34.89 |
| BCAX Bicara Therapeutics Inc. Common Stock | $1.81B | — | $16.78 | ▼ 4.77% | $13.7$30.99 |
| ANIP ANI Pharmaceuticals Inc. | $1.86B | 15.16 | $72.29 | ▲ 0.01% | $69.58$97 |
| NAMSW NewAmsterdam Pharma Company N.V. Warrant | $1.87B | — | $9 | ▼ 17.81% | $9.79$30.45 |
| KARD Kardigan Inc. Common Stock | $1.79B | — | $13.03 | ▼ 6.12% | $12.23$27 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Compass Pathways Reports Q2 2026 Results: Full Earnings Call Transcriptbenzinga · 10/8/2026
- Compass Pathways Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga · 10/8/2026
- Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/2/2026
- COMPASS Pathways (CMPS) Could Be 49% Below Fair Value Following Its Phase III ProgressYahoo · 10/1/2026
- Compass Pathways Appoints Kelley Boucher as Chief People OfficerYahoo · 9/30/2026
- Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 LaunchYahoo · 9/25/2026
- Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major DepressionYahoo · 9/24/2026
- Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression DataYahoo · 9/22/2026
- Compass Pathways Eyes 2027 COMP360 Launch as FDA Review AdvancesYahoo · 9/22/2026
Insider Activity
Insider Actions →- Nath Kabir · August 3, 2026 · Tax Withholding6.0K @ $11.25
- Gino Santini · May 27, 2026 · Grant30.2K
- JONAS JEFFREY M · May 27, 2026 · Grant21.1K
- McQuade Robert · May 27, 2026 · Grant21.1K
- Tregoning Kathleen · May 27, 2026 · Grant41.1K
- Daphne Karydas · May 27, 2026 · Grant21.1K
- Gover Justin D. · May 27, 2026 · Grant21.1K
- Norton David Y · May 27, 2026 · Grant21.1K
- Riley Wayne Joseph · May 27, 2026 · Grant21.1K
Institutional Ownership
March 31, 2026
- Total shares held
- 97.77M
- Total value held
- $539.33M
- Institutional holders
- 193
- Unknown12.16M
- Unknown10.63M
- Unknown4.04M
- Unknown4.00M
- Unknown3.61M
- Unknown3.49M
- Unknown3.39M
- Unknown3.30M
- Unknown3.14M
- Unknown3.08M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Compass Pathways Q2 2026 Earnings Released Amid Low RSI
Compass Pathways has released its Q2 2026 results, providing the latest financial update for the company. The news cycle also includes broader sector commentary on pipeline risks, though specific details for Compass remain focused on the earnings release. The stock is currently trading near its 52-week low, reflecting recent market sentiment.
Compass Pathways Q2 2026 Earnings Released Amid Low RSI. Compass Pathways has released its Q2 2026 results, providing the latest financial update for the company. The news cycle also includes broader sector commentary on pipeline risks, though specific details for Compass remain focused on the earnings release. The stock is currently trading near its 52-week low, reflecting recent market sentiment.